Northwest Clinical Research Center

Running trials

• Not yet recruiting

  A Study of Brenipatide in Participants With Major Depressive Disorder

  NCT07928245· Phase 2· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

  NCT07775300· Phase 3· Source

• Recruiting

  A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

  NCT07716098· Phase 3· Source

• Recruiting

  A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

  NCT07602582· Phase 3· Source

• Recruiting

  A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

  NCT07573176· Phase 3· Source

• Recruiting

  AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  NCT07509307· Phase 3· Source

• Recruiting

  A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  NCT07481630· Phase 3· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Schizophrenia

  NCT07410507· Phase 2· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Major Depressive Disorder

  NCT07412756· Phase 3· Source

• Recruiting

  Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

  NCT07494305· Phase 2· Source

• Active, not recruiting

  Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

  NCT07225686· Phase 3· Source

• Active, not recruiting

  Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

  NCT07226765· Phase 3· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

  NCT07286175· Phase 2· Source

• Active, not recruiting

  A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

  NCT07215559· Phase 2· Source

• Recruiting

  A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

  NCT07202884· Phase 3· Source

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

  NCT07153471· Phase 3· Source

• Active, not recruiting

  A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

  NCT06859268· Phase 3· Source

• Recruiting

  Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

  NCT06847321· Phase 2· Source

• Recruiting

  Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients

  NCT06690398· Phase 3· Source

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Source

• Recruiting

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· Phase 3· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

  NCT06540833· Phase 2· Source

• Recruiting

  Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

  NCT06372964· Phase 3· Source

• Recruiting

  Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

  NCT06229210· Phase 3· Source

• Active, not recruiting

  A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

  NCT06037252· Phase 2· Source

• Recruiting

  Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

  NCT05850689· Phase 3· Source

• Active, not recruiting

  A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

  NCT05738486· Phase 3· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Source

• Recruiting

  Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

  NCT04743141· Phase 3· Source

• Recruiting

  Randomized Study in Children and Adolescents With Migraine: Acute Treatment

  NCT04649242· Phase 3· Source

• Active, not recruiting

  A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

  NCT04616326· Phase 3· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Source

• Active, not recruiting

  A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

  NCT03432286· Phase 3· Source

• Active, not recruiting

  Escitalopram for Agitation in Alzheimer's Disease

  NCT03108846· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression7 recruiting
• Alzheimer disease4 recruiting
• Bipolar disorder4 recruiting
• Schizophrenia4 recruiting
• Obesity3 recruiting
• Autism2 recruiting
• Migraine2 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)

  NCT07258485· Source

• Withdrawn

  A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

  NCT06901349· Phase 2· Source

• Recruiting

  Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

  NCT06547489· Phase 2· Source

• Completed

  A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  NCT06649045· Phase 3· Source

• Completed

  Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

  NCT06603623· Phase 2· Source

• Completed

  A Study to Test Different Doses of BI 1569912 in People With Depression

  NCT06558344· Phase 2· Source

• Completed

  Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

  NCT06568042· Phase 2· Source

• Completed

  Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

  NCT06423781· Phase 2· Source

• Completed

  Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

  NCT06419608· Phase 2· Source

• Completed

  A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

  NCT06373146· Phase 2· Source

• Terminated

  Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

  NCT06304883· Phase 3· Source

• Completed

  A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

  NCT06254612· Phase 2· Source

• Completed

  A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

  NCT05931367· Phase 3· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

  NCT05929079· Phase 3· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

  NCT05929066· Phase 3· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Source

• Completed

  A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05550532· Phase 3· Source

• Completed

  Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

  NCT05518123· Phase 4· Source

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Source

• Completed

  Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

  NCT05509400· Phase 4· Source

• Completed

  A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

  NCT05463731· Phase 3· Source

• Completed

  A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05455684· Phase 3· Source

• Terminated

  Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

  NCT05267535· Phase 2/3· Source

• Completed

  A Study of JNJ-55308942 in the Treatment of Bipolar Depression

  NCT05328297· Phase 2· Source

• Terminated

  Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT05026177· Phase 3· Source

• Completed

  A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05145413· Phase 3· Source

• Terminated

  Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention

  NCT05016661· Phase 2· Source

• Completed

  Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

  NCT04846881· Phase 3· Source

• Completed

  An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

  NCT04820309· Phase 3· Source

• Completed

  An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

  NCT04770220· Phase 3· Source

• Terminated

  A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

  NCT04804033· Phase 2/3· Source

• Completed

  Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

  NCT04845178· Phase 2· Source

• Completed

  Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT03393520· Phase 3· Source

• Terminated

  Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT02446132· Phase 3· Source